Hepatitis B Vaccination and Rituximab Management
For patients requiring rituximab therapy, hepatitis B vaccination should ideally be completed BEFORE starting rituximab, as vaccination during or after rituximab therapy results in poor to absent immune responses. If rituximab is already ongoing, defer non-influenza vaccinations until the next rituximab dose is due, then hold rituximab for at least 2 weeks after vaccination to allow immune response development 1.
Pre-Rituximab Vaccination Strategy
Complete hepatitis B vaccination series before initiating rituximab whenever possible. This is the optimal approach as:
- Patients vaccinated during rituximab therapy show minimal to no seroconversion 2
- In one prospective study, none of the HBV-naive patients seroconverted when vaccinated before rituximab chemotherapy 2
- Vaccination while not on biological agents reduces the need for boosters and revaccination 3
Dosing for Immunocompromised Patients
Use higher antigen doses as recommended by ACIP for immunocompromised patients 4. Check post-vaccination anti-HBs titers 1-2 months after the last dose, and repeat the vaccine series if anti-HBs concentrations >10 mIU/mL are not achieved 4.
During Rituximab Therapy
If vaccination must occur during rituximab:
- Time vaccination for when the next rituximab dose is due
- Hold rituximab for at least 2 weeks after vaccination (if disease activity allows) 1
- This approach improves vaccine immunogenicity, though responses remain suboptimal
Critical caveat: Even with optimal timing, patients on rituximab require more boosters and second vaccine series to achieve seroconversion, with success rates exceeding 80% only after multiple attempts 3. Being on rituximab was specifically associated with failure to seroconvert 3.
Mandatory HBV Screening Before Rituximab
Screen ALL patients for HBV infection before initiating rituximab by measuring HBsAg and anti-HBc 5. This is an FDA-mandated requirement due to the exceptionally high risk of HBV reactivation with rituximab.
Why This Matters:
- Without prophylaxis, 59% of HBsAg-positive patients experience hepatitis flares (24.5 per 100 person-years) and 8% develop liver decompensation 6
- Rituximab carries 50-64% risk of HBV reactivation regardless of underlying disease or HBsAg status 7
- Reactivation risk continues for at least 2 years after rituximab therapy 7
For Patients with Resolved HBV (Anti-HBs Positive):
Patients with anti-HBs ≥100 mIU/mL before immunosuppression had no antibody loss, while 18% with anti-HBs <100 mIU/mL lost protective antibodies 2. This suggests potential for risk stratification, though current guidelines still recommend universal antiviral prophylaxis for chronic HBV patients receiving rituximab.
Post-Rituximab Considerations
If antiviral prophylaxis is discontinued after rituximab completion, continue for at least one additional year 6. Stopping antivirals within one year post-rituximab resulted in 38% flare rate even without further rituximab treatment. Rituximab "retreatment" after antiviral discontinuation led to 75% flare rate and 63% liver decompensation 6.
Common Pitfalls to Avoid
- Do not assume vaccination during rituximab will provide adequate protection - responses are severely blunted or absent
- Do not skip HBV screening - this is mandatory per FDA labeling and prevents life-threatening reactivation
- Do not stop antivirals too early - maintain for at least 12 months after last rituximab dose
- Do not forget that reactivation risk persists for years - surveillance must continue long-term